The recent announcements in three U.S. Department of Justice (“DOJ”) national security prosecutions offer an early glimpse into some of the Trump Justice Department’s enforcement priorities. Indeed, these actions are consistent with the announced priorities of Attorney General Pamela Bondi, as set...
[Printable Version] Executive Summary We entered 2025 with the world in turmoil, a new American administration in the White House, and various global actors—friends and foes alike—still actively vying for the attention of the American public. The scene is set for a continued parade of foreign actors...
What You Need to Know Attorney General Pam Bondi sets the tone with the issuance of 14 new Department of Justice memoranda on her first day on the job. Attorney General Pam Bondi’s memorandum on charging, pleas, and sentencing identifies the new administration’s key enforcement priorities, with some...
Introduction On December 20, 2024, the U.S. Department of Justice (DOJ) announced its long-awaited proposed amendments to the regulations adopted under the Foreign Agents Registration Act (FARA) in a Notice of Proposed Rulemaking (NPRM) submitted to the Federal Register. [1] FARA (the “FARA Statute...
Introduction In May 2022, a jury in the Circuit Court for Fairfax County, Virginia awarded Appian Corp. (Appian) in excess of $2 billion in damages from Pegasystems, Inc. (Pegasystems) for misappropriating Appian’s trade secrets in violation of the Virginia Uniform Trade Secrets Act (VUTSA). This...
Introduction On June 18, 2024, the Federal Trade Commission (“FTC”) unanimously agreed to submit a comment supporting a recent proposed U.S. Patent and Trademark Office (“PTO”) rule that would mandate the disclosure of all settlement agreements made between parties appearing before the Patent Trial...
On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...